ReviewCancers2019
Sestrins as a Therapeutic Bridge between ROS and Autophagy in Cancer.
Review in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 54 citations in OpenAlex.
- Single-cell analysis of the progeria arterial wall reveals progerin-induced progressive, cell type-specific dysfunction and somatic mutation accumulation.Genome medicine · 2026Article
- A TP53-Pathway-Based Prognostic Signature for Radiotherapy and Functional Validation of TP53I3 in Non-Small-Cell Lung Cancer.Cancers · 2026Article
- A resource of "bottom-line" variant associations for 1,281 complex traits by integrating data across published genome-wide association studies.Research square · 2026Article
- Mechanistic insights and therapeutic strategies for targeting autophagy in pancreatic ductal adenocarcinoma.Discover oncology · 2025Review
- Oxidative Stress and Autophagy: Unraveling the Hidden Threat to Boars' Fertility.Antioxidants (Basel, Switzerland) · 2024Review
- Article
- Role of sestrins in metabolic and aging-related diseases.Biogerontology · 2024Review
- The oncogenic miR-429 promotes triple-negative breast cancer progression by degrading DLC1.Aging · 2023Article
- Review
- Advanced Delivery System of Polyphenols for Effective Cancer Prevention and Therapy.Antioxidants (Basel, Switzerland) · 2023Review
- Discovery of BAR502, as potent steroidal antagonist of leukemia inhibitory factor receptor for the treatment of pancreatic adenocarcinoma.Frontiers in oncology · 2023Article
- Understanding the Impact of Obesity on Ageing in the Radiance of DNA Metabolism.The journal of nutrition, health & aging · 2023Review
- SESN2 Knockdown Increases Betulinic Acid-Induced Radiosensitivity of Hypoxic Breast Cancer Cells.Cells · 2022Article
- Article
- Design, synthesis, and biological evaluation of tetrahydroquinolinones and tetrahydroquinolines with anticancer activity.Scientific reports · 2022Article
- ROS: Basic Concepts, Sources, Cellular Signaling, and its Implications in Aging Pathways.Oxidative medicine and cellular longevity · 2022Review
- Serum Sestrin2 Was Lower in Septic Shock Patients with Cardiomyopathy.Disease markers · 2022Article
- The Role of Oxidative Stress in the Pathogenesis of Vitiligo: A Culprit for Melanocyte Death.Oxidative medicine and cellular longevity · 2022Review
- Redox Sensitive Cysteine Residues as Crucial Regulators of Wild-Type and Mutant p53 Isoforms.Cells · 2021Review
- Autophagy and the Lysosomal System in Cancer.Cells · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 3 countries.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.